FOLFOX-4 most effective, expensive in colon cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.594, 2010-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Colon cancer: deciding on the most cost-effective strategy

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 245, 2000-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

XELOX dominant over FOLFOX4 for colorectal cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 585, 2009-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

FOLFOX4: clear benefit in colorectal cancer

Inpharma, Vol. 1, Iss. 1347, 2002-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

FOLFOX4 feasible first-line therapy for advanced gastric cancer

Inpharma, Vol. 1, Iss. 1498, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Adding cytokine-induced killer (CIK) cell therapy to the FOLFOX4 regimen is beneficial for treating advanced gastric cancer

Inpharma, Vol. 1, Iss. 1548, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite